唑来膦酸改善胃癌患者的生存。
Zolbetuximab Improves Survival in Gastric Cancer.
出版信息
Cancer Discov. 2023 Mar 1;13(3):520-521. doi: 10.1158/2159-8290.CD-NB2023-0006.
Abstract
Results from the phase III SPOTLIGHT trial show that the investigational mAb zolbetuximab plus chemotherapy improves progression-free survival and overall survival in patients newly diagnosed with claudin 18.2-positive, HER2-negative locally advanced inoperable or metastatic gastric or gastroesophageal junction cancer. The drug could become a standard treatment option for these patients.
摘要
III 期 SPOTLIGHT 试验的结果表明，研究性单克隆抗体 zolbetuximab 联合化疗可改善新诊断的 Claudin 18.2 阳性、HER2 阴性局部晚期不可切除或转移性胃或胃食管交界处癌患者的无进展生存期和总生存期。该药有望成为此类患者的标准治疗选择。
Zotero 插件